ALPMY
HOLD
Conviction: 2/5
$28B
Astellas Pharma
Current: $14.5 · PT: $16
Investment Thesis
Japanese pharma transitioning from Xtandi dominance to diversified portfolio. Strategic brands (Padcev, Izervay, Veozah, Vyloy, Xospata) growing rapidly. Xtandi ($6B) faces US LOE in 2027 - major cliff risk. Padcev partnership with Pfizer is key growth driver in bladder cancer.
Bull Case
Strategic brands exceed expectations, offsetting Xtandi decline. Padcev becomes $4B+ drug in bladder cancer. Vyloy expands to pancreatic cancer. Pipeline delivers in oncology/rare disease.
Bear Case
Xtandi cliff steeper than expected. Padcev competition from other ADCs. Vyloy limited by CLDN18.2 testing adoption. Pipeline setbacks in early-stage assets.
Drug Portfolio (9)
Oncology
Small molecule
PO
Ophthalmology
Pegylated aptamer
Intravitreal
Oncology
Small molecule
PO
Immunology
Small molecule
PO
| Drug | Stage | Role | Ownership | Area | Modality |
|---|
| ASP3082 | PHASE1 | ORIGINATOR | 100% | Oncology | Small molecule |
Financials (USD)
| Period | Revenue ($M) | Gross Margin | R&D | SG&A | Op Income | Op Margin | Net Income | EPS |
|---|
| 2026E | $12,667 | — | $0 | $0 | $2,667 | 21.1% | $2,000 | $2.45 |
| 2027E | $11,667 | — | $0 | $0 | $2,133 | 18.3% | $1,600 | $1.95 |
| 2028E | $12,333 | — | $0 | $0 | $2,533 | 20.5% | $1,900 | $2.30 |
| FY2023A | $10,715 | 72.0% | $1,867 | $3,200 | $2,017 | 18.8% | $1,497 | $1.80 |
| FY2024A | $12,749 | 78.0% | $2,133 | $3,467 | $2,616 | 20.5% | $1,971 | $2.40 |
| FY2025E | $13,533 | 79.0% | $0 | $0 | $3,267 | 24.1% | $2,433 | $2.95 |
Recent Quarters
| Quarter | Revenue ($M) | Gross Margin | Op Margin | EPS |
|---|
| Q4 FY2025E | $2,860 | 79.0% | 11.2% | $0.26 |
| Q3 FY2025 | $3,873 | 79.0% | 33.0% | $1.18 |
| Q2 FY2026E | $3,200 | 79.0% | 20.8% | $0.61 |
| Q2 FY2025 | $3,600 | 78.9% | 26.9% | $0.90 |
| Q1 FY2026E | $3,067 | 79.0% | 19.6% | $0.55 |
| Q1 FY2025 | $3,200 | 78.0% | 21.9% | $0.63 |
Catalysts (11)
PADCEV + Keytruda - MIBC - Japan sNDA Filed
REGULATORY
astellas.com newsroom Jan 30, 2026
Jan 30, 2026
ASP3082 (Setidegrasib) - Pancreatic Cancer - Ph3 - Start
CLINICAL
SM
Astellas JPM 2026, AACR-NCI-EORTC 2025 data
By Mar 2026
Veozah - Commercial Uptake Updates
COMMERCIAL
Astellas Q3 FY2025 Earnings
2026
Xospata - Commercial Updates
COMMERCIAL
Astellas Q3 FY2025 Earnings
2026
PADCEV + Keytruda - Cis-Ineligible MIBC - EMA Approval
REGULATORY
SM
astellas.com newsroom, EMA CHMP review ongoing
2026
Vyloy - Global Launch Trajectory
COMMERCIAL
Astellas JPM 2026, Q3 FY2025 Earnings
2026
ASP2138 - Gastric Cancer - Ph1 - Updates
CLINICAL
Astellas JPM 2026, ASCO GI 2026
2026
ASP3082 - NSCLC - Registrational Study Preparation
CLINICAL
Astellas JPM 2026, Oncology Pipeline Meeting Oct 2025
2026
Vyloy + Keytruda + Chemo - 1L Gastric - Ph3 - Updates (LUCERNA)
CLINICAL
SM
ClinicalTrials.gov NCT06901531, Astellas JPM 2026
2027+
XTANDI - US Patent Expiration Preparation
COMPETITIVE
SM
Astellas JPM 2026 (CEO Okamura), Q3 FY2025 Earnings
US: 2027
ALPMY - 30% Core OP Margin Target
GUIDANCE
Astellas JPM 2026 (CEO Okamura)
FY2027
Open Debates (2)
Underappreciated Risk: Xtandi US LOE in 2027 — Magnitude of Cliff
Bull
Strategic brands (Padcev, Izervay, Veozah, Vyloy, Xospata) growing fast enough to offset. Padcev ($1.1B FY24) could reach $4B. The diversification strategy is well-executed.
Bear
Xtandi is $6.1B — the largest single drug. It contributes disproportionately to profits given its mature cost structure. Generic enzalutamide will erode 80%+ of US revenue within 2 years of LOE. That is a ~$3B revenue and ~$2.5B profit hole. Strategic brands combined are still only ~$2.2B and growing off small bases. The math does not work in 2028-2029 without a miracle.
Conviction: 5/5
Underappreciated Growth Driver: Izervay in Geographic Atrophy
Bull
Izervay ($389M FY24) is competing against Apellis's Syfovre in geographic atrophy — a massive underserved market (~1M patients in the US alone). Syfovre has safety concerns (vasculitis, potential conversion to wet AMD) that are driving physician preference toward Izervay. GA requires monthly injections for life — high LTV per patient. The $2.5B peak could prove conservative if Syfovre safety issues drive further market share shift.
Bear
GA progression is slow, making patients question benefit vs injection burden. Neither Syfovre nor Izervay fully halts progression — they slow it. Patient dropout rates are high. The addressable market may be smaller than the diagnosed population.
Conviction: 5/5
Data from Supabase · Updated 2026-03-24